Thymopentin versus placebo in a multicenter rheumatoid arthritis trial
Randomized study in people · 1988
- What was studied
- 119 randomized participants with rheumatoid arthritis. The analysis included 107 participants (51 thymopentin and 56 placebo).
- Main finding
- Steinbrocker functional class · Improved in 7/51 thymopentin recipients versus 0/56 placebo recipients.
Reported findings and study design
Reported findings
Double-blind, multicenter placebo comparison. Thymopentin 50 mg by intravenous injection over 10 minutes three times per week for three weeks, with four additional weeks of observation.
Population or model 119 randomized participants with rheumatoid arthritis. The analysis included 107 participants (51 thymopentin and 56 placebo).
Dose, route and schedule
Double-blind, multicenter placebo comparison. Thymopentin 50 mg by intravenous injection over 10 minutes three times per week for three weeks, with four additional weeks of observation.
Protocol source ↗ · English abstract of the original German article. A full copy was unavailable for extraction.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Steinbrocker functional class | Improved in 7/51 thymopentin recipients versus 0/56 placebo recipients. | |
| Clinical and laboratory measures | Five of nine clinical criteria showed improvement at week three. The authors report a higher frequency of improvement of at least 40% in individual clinical criteria, without giving the response counts. Effects diminished over the next four weeks and laboratory measures did not change. | |
| Safety | One systemic allergic reaction was reported. |
Twelve randomized participants were omitted from the analysis. The abstract provides limited per-endpoint data, and the brief follow-up leaves effects on lasting disability and joint damage unresolved.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- Twelve randomized participants were omitted from the analysis. The abstract provides limited per-endpoint data, and the brief follow-up leaves effects on lasting disability and joint damage unresolved.
Source details
English abstract of the original German article. A full copy was unavailable for extraction.
Sources checked
Added to the library
Citation
E. M. Lemmel, G. L. Bach, W. Bolten, D. Brackertz, Z. Fahmy, H. Mattern, I. Stroehmann, A. Wittenborg. Thymopentin versus placebo in a multicenter rheumatoid arthritis trial Deutsche Medizinische Wochenschrift 113(5), 172–176
Study source ↗ · DOI 10.1055/s-2008-1067614 · Bibliography entry · Link to this summary